Developing evidence to inform the clinical utility and cost-effectiveness of pharmacogenomic markers: challenges and opportunities
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: SORICH, Michael (Flinders University, Clinical Pharmacology, Adelaide, Australia)
Background: Despite extensive research the clinical translation of pharmacogenomics has been less than expected. One of the key factors identified is the quality of the evidence supporting the clinical utility and cost-effectiveness of pharmacogenomic markers. A better general appreciation of these issues is valuable in setting more realistic.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.